Example: Heart Attack

Clinical Trials on Chronic Lymphocytic Leukemia

Total 1862 results

NCT04560322

Not yet recruiting

Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT04545333

Not yet recruiting

The clonoSEQ® Watch Registry

Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Chronic Lymphocytic Leukemia; Multiple Myeloma; Non-hodgkin Lymphoma
NCT04545762

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Conditions: Refractory Non-Hodgkin Lymphoma; Burkitt Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Lymphoplasmacytic Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Diffuse Large B Cell Lymphoma; Small Lymphocytic Lymphoma; Transformed Lymphoma
NCT04542824

Recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL

Conditions: Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma
NCT04540796

Not yet recruiting

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Conditions: Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
NCT04523428

Not yet recruiting

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Conditions: CLL/SLL
NCT04516551

Recruiting

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Conditions: Relapsed Adult ALL; B Cell Leukemia
NCT04515238

Not yet recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Conditions: Chronic Lymphoid Leukemia
NCT04512105

Not yet recruiting

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; AML, Adult; CLL; CLL, Relapsed; CLL, Refractory
NCT04505254

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT04504708

Not yet recruiting

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Conditions: Non-hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT04501939

Not yet recruiting

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Conditions: Chronic Lymphocytic Leukemia
NCT04502030

Not yet recruiting

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Conditions: Chronic Lymphocytic Leukemia; Hypogammaglobulinemia
NCT04502394

Not yet recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Conditions: Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma
NCT04494503

Not yet recruiting

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT04488354

Not yet recruiting

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Conditions: Relapsed/Refractory B-cell Lymphomas; Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Chronic Lymphocytic Leukemia (CLL); Marginal Zone Lymphoma (MZL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma (SLL); Primary Mediastinal Large B Cell Lymphoma; Transformed Follicular Lymphoma
NCT04477291

Not yet recruiting

A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT04464200

Recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Conditions: Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Indolent Non-Hodgkin Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia; Burkitt's Lymphoma; Primary CNS Lymphoma
NCT04458610

Recruiting

BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patient

Conditions: Chronic Lymphocytic Leukemia (CLL)
NCT04450069

Recruiting

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Conditions: Relapsed/Refractory B-cell Lymphomas; Diffuse Large B Cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Chronic Lymphocytic Leukemia (CLL); Marginal Zone Lymphoma (MZL); Mantle Cell Lymphoma; Small Lymphocytic Lymphoma (SLL); Primary Mediastinal Large B Cell Lymphoma; Transformed Follicular Lymphoma
NCT04447768

Not yet recruiting

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Conditions: Chronic Lymphocytic Leukemia (CLL)
NCT04434196

Recruiting

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions: Lymphoma, Non-Hodgkin
NCT04419389

Recruiting

APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL)

Conditions: Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
NCT04419519

Recruiting

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
NCT04407845

Recruiting

Atrial Fibrillation in Patients Receiving Ibrutinib

Conditions: Leukemia, Chronic Lymphatic; Mantle Cell Lymphoma
NCT04391946

Recruiting

Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19

Conditions: Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease
NCT04370457

Not yet recruiting

MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies

Conditions: Chronic Lymphocytic Leukemia; Myelodysplastic Syndromes
NCT04356846

Recruiting

A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Conditions: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia
NCT04342117

Recruiting

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

Conditions: Lymphoma, Small Lymphocytic; Lymphoma; Lymphoma, Non-Hodgkin; Chronic Lymphocytic Leukemia; Follicular Lymphoma
NCT04312841

Not yet recruiting

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Conditions: B-Cell Prolymphocytic Leukemia; Chronic Lymphocytic Leukemia; Peripheral T-Cell Lymphoma; Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; T-Cell Prolymphocytic Leukemia
NCT04305444

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Conditions: Relapsed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Richter's Transformation
NCT04290923

Recruiting

Determination of Blood Tumor Cells

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Abnormalities Cell Epithelial
NCT04285567

Recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Conditions: Chronic Lymphocytic Leukemia (CLL)
NCT04282811

Not yet recruiting

Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Conditions: Chronic Lymphocytic Leukemia; Relapse Leukemia; Refractory Leukemia
NCT04282018

Recruiting

Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Advanced Solid Tumor; Non-small Cell Lung Cancer; Metastatic Melanoma
NCT04282174

Not yet recruiting

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Conditions: Hematologic Diseases; Hematologic Malignancy; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia
NCT04282343

Not yet recruiting

DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer

Conditions: Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Plasma Cell Myeloma
NCT04279405

Not yet recruiting

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Conditions: Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma
NCT04269902

Not yet recruiting

Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT04271410

Recruiting

CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Conditions: Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-cell; Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
NCT04271800

Recruiting

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Conditions: Leukemia; Lymphoma; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
NCT04260945

Recruiting

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

Conditions: B-cell Leukemia
NCT04245722

Recruiting

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Conditions: Lymphoma, B-Cell; Chronic Lymphocytic Leukemia
NCT04240704

Recruiting

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Conditions: Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia
NCT04230304

Recruiting

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Conditions: Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma
NCT04233346

Recruiting

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
NCT04215367

Completed

Dietary Intervention With High Phenolic EVOO in CLL

Conditions: Chronic Lymphocytic Leukemia (CLL)
NCT04215809

Recruiting

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Conditions: CLL/SLL
NCT04209621

Recruiting

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions: Small Lymphocytic Leukemia (SLL); Chronic Lymphocytic Leukemia (CLL)
NCT04210219

Recruiting

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Conditions: Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell

COOKIE SETTINGS

Clinical Trials on Chronic Lymphocytic Leukemia